Skip to search boxSkip to navigationSkip to main content

Metformin does not affect risk of biochemical recurrence following radical prostatectomy: Results from the SEARCH database

  • E. H. Allott
    ,
  • M. R. Abern
    ,
  • L. Gerber
    ,
  • C. J. Keto
    ,
  • W. J. Aronson
    ,
*Corresponding author for this work
  • Duke University
    ,
  • Durham Veterans Affairs Medical Center
    ,
  • Department of Veterans Affairs
    ,
  • University of California at Los Angeles
    ,
  • Augusta University
    ,
  • VA Medical Center
Scholary Output:
Contribution to journal
Article
Research
Peer-review

Open access

Sustainable Development Goals

  • SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well

Abstract

<p>Background:While epidemiologic studies suggest that metformin use among diabetics may decrease prostate cancer (PC) incidence, the effect of metformin use on PC outcome is unclear. We investigated the association between pre-operative metformin use, dose and duration of use and biochemical recurrence (BCR) in PC patients with diabetes who underwent radical prostatectomy (RP).Methods:We conducted a retrospective cohort analysis within the Shared Equal Access Regional Cancer Hospital (SEARCH) database of 371 PC patients with diabetes who underwent RP. Time to BCR between metformin users and non-users, and by metformin dose and duration of use was assessed using multivariable Cox proportional analysis adjusted for demographic, clinical and/or pathologic features. Time to castrate-resistant PC (CRPC), metastases and PC-specific mortality were explored as secondary outcomes using unadjusted analyses.Results:Of 371 diabetic men, 156 (42%) were using metformin before RP. Metformin use was associated with more recent year of surgery (P<0.0001) but no clinical or pathologic characteristics. After adjustment for year of surgery, clinical and pathologic features, there were no associations between metformin use (hazard ratio (HR) 0.93; 95% confidence interval (CI) 0.61-1.41), high metformin dose (HR 0.96; 95% CI 0.57-1.61) or duration of use (HR 1.00; 95% CI 0.99-1.02) and time to BCR. A total of 14 patients (3.8%) developed CRPC, 10 (2.7%) distant metastases and 8 (2.2%) died from PC. Unadjusted analysis suggested that high metformin dose vs non-use was associated with increased risk of CRPC (HR 5.1; 95% CI 1.6-16.5), metastases (HR 4.8; 95% CI 1.2-18.5) and PC-specific mortality (HR 5.0; 95% CI 1.1-22.5).Conclusions:Metformin use, dose or duration of use was not associated with BCR in this cohort of diabetic PC patients treated with RP. The suggestion that higher metformin dose was associated with increased risk of CRPC, metastases and PC-specific mortality merits testing in large prospective studies with longer follow-up.</p>

Publication Information

Output type

Scholary Output:
Contribution to journal
Article
Research
Peer-review

Original language

English (US)

Pages from-to (Number of pages)

Pages 391-397 (7 pages)

Journal (Volume, Issue Number)

Prostate Cancer and Prostatic Diseases (Volume 16, Issue 4)

Publication milestones

  • Published - 12/2013

Publication status

Published - 12/2013

ISSN

1365-7852

Publication IDs

  • Scopus: 84887610935
  • PubMed: 24100644

Publication metrics

Metrics

SciVal
FWCI
3.02
SciVal
Author count
11
SciVal
citations
44
SciVal
Paper percentile
92
SciVal
Top percentile
10
Scopus
citations
Fractional count
1
Fractional count
0.09
Fractional count
10
Fractional count
0.91
Fractional count
1
Fractional count
1

PlumX, opens in new tab

Citation count
51
Captures
32

Funding Details

This study was supported by EHA: NCI 5R25-CA126938-03; SJF: NIH Grant 1-R01-CA131235-01A1 and NIH 1K24CA160653.
FundersFunding numbers
NIH
-
EHA
-
NCI
R01CA131235, R25CA126938, P50CA092131, K24CA160653